A key challenge in the treatment of advanced non-small-cell lung cancer (NSCLC) is improving outcomes for patients who have achieved at least stable disease after standard first-line therapy. Although current guidelines recommend a maximum of six cycles of first-line therapy, even in responding patients, recent trials have shown benefit with maintenance therapy.
INTRODUCTION
An estimated 215,000 new instances of lung cancer were diagnosed in the United States in 2008, 1 with most of these cases (Ͼ 80%) categorized as nonsmall-cell lung cancer (NSCLC). The majority of patients with NSCLC present with locally advanced (Ϸ 35%) or metastatic disease (Ϸ 40%), 1 and in this palliative setting balancing efficacy with toxicity is of the utmost importance.
Platinum-based doublets are the mainstay of standard chemotherapy for patients with good performance status who have advanced NSCLC. 2, 3 Adding targeted agents, such as bevacizumab 4 or cetuximab, 5 to standard chemotherapy can, in selected groups of patients, increase the overall survival (OS).
The purpose of this article is to review recent studies that have evaluated strategies aimed at prolonging the duration of chemotherapy in eligible patients with NSCLC, and to discuss the advantages/ disadvantages and current clinical objectives of the different approaches.
METHODS
Information for this review was derived from a search of the PubMed database using the following search strategy: (NSCLC AND [advanced OR metastatic]) AND (sequential OR prolonged OR strategy OR second-line OR schedule OR maintenance). The search was restricted to randomized controlled trials (RCT) published in English between January 1999 and January 2010. Primary citations were hand searched and relevant secondary publications identified. The search was supplemented by a review of
Continuation Therapy
Continuation in the context of strategies for prolonging therapy in advanced NSCLC involves continuing the first-line regimen until disease progression, unacceptable toxicity, or administration of a predefined greater number of treatment cycles.
A number of studies reported that continuation of initial chemotherapy beyond 4 to 6 cycles is not associated with improved response rate or survival, even in patients with stable or responsive disease. The first study was the randomized trial conducted by Smith et al. 9 In this trial, patients were randomly assigned to either 3 or 6 cycles of mitomycin, vinblastine, and cisplatin. There were no differences between the two regimens in terms of median survival (6 v 7 months), 1-year survival (22% v 25%), or duration of symptom relief (4.5 months in both groups), while some QoL measures were better in the 3-cycle arm. While more than 70% of the patients completed 3 cycles of therapy, fewer than one third were able to receive 6 cycles. The study conducted by Socinski et al 10 compared a regimen of carboplatin and paclitaxel given every 3 weeks for either 4 cycles (arm A) or continuously until progression (arm B). Patients received second-line treatment (after the scheduled 4 cycles in arm A or at progression in arm B) comprising weekly paclitaxel 80 mg/m 2 . There were no significant differences between the two arms in terms of OS (6.6 v 8.5 months; P ϭ .63) or QoL, as measured using the Functional Assessment of Cancer Therapy-Lung instrument. Moreover, clinically relevant neuropathy was much more common in patients receiving prolonged paclitaxel (27% v 14%). The lack of a significant difference in survival between the study arms was evident both in the overall population and when comparing subgroups of patients who had received at least 4 treatment cycles.
In the other study, von Plessen et al evaluated carboplatin (area under the curve, 4 by Chatelut, day 1) plus vinorelbine (25 mg/m 2 , days 1 and 8) every 3 weeks given for either 3 or 6 cycles. 11 Although the results of these studies were indicative of a lack of benefit with continuation chemotherapy in patients with advanced NSCLC, it is important to note that the majority of patients randomly assigned to longer courses of chemotherapy did not receive the planned number of cycles because of toxicity or disease progression. In the study by Socinski, only 57% of patients in arm A completed the scheduled 4 cycles of therapy, while in the continuous treatment arm, the median number of cycles administered was 4 (range, 0 to 19), with 42% and 18% of patients receiving more than 4 and Ն 8 cycles, respectively. In the study by von Plessen, 78% to 79% of patients across the study completed 3 cycles of therapy; however, only 54% of patients assigned to the longer regimen completed 6 cycles of therapy.
Continuation-Maintenance Therapy
Ongoing administration of a lower intensity version of the first-line regimen can be termed continuation-maintenance therapy. Because it uses a less intensive regimen, maintenance therapy could facilitate more consistent delivery of chemotherapy compared with continuation therapy.
In a study conducted by Belani et al 12 , patients were initially randomly assigned to one of three paclitaxel/carboplatin regimens (Tables 1 and 2) . [12] [13] [14] [15] Patients who responded after 4 cycles were randomly assigned to either weekly low-dose paclitaxel or to observation only. Although the study was not powered to compare outcomes during the maintenance phase, both time to progression (38 v 29 weeks) and OS (75 v 60 weeks) were longer in patients who received maintenance paclitaxel. Another trial evaluated maintenance gemcitabine versus best supportive care (BSC) after induction treatment with 4 cycles of gemcitabine and cisplatin. 13 Patients with responsive or stable disease were randomly assigned to maintenance gemcitabine or to BSC only. Time to progression, which was the primary end point, was significantly longer for patients who received maintenance therapy, both throughout the entire study period (6.6 v 5 months; P Ͻ .001) and during the randomization period (3.6 v 2 months). There was also a trend toward longer OS throughout the entire study in the maintenance gemcitabine group. The study noted no significant differences in QoL between the two arms.
Two additional studies with maintenance gemcitabine were recently reported. 14, 15 In the first study, patients with stable or responsive disease were randomly assigned to either gemcitabine with BSC or BSC alone. The study closed after 6 years due to slow accrual, at which point 179 of the 238 planned events had occurred. Moreover, a large portion of the patients in both cohorts had a performance status (PS) of 2 to 3. Not surprisingly, the rate of secondline therapy for the control group was very low, at 17%. There was no difference in PFS, calculated from first-line therapy (maintenance, 7.4 months; BSC, 7.7 months), or OS (maintenance, 8 months; BSC 9.3 months). It appears that poor PS patients may not be good candidates for ongoing chemotherapy. The second study, however, showed a strong PFS benefit for those patients, who continued gemcitabine after four cycles of cisplatin and gemcitabine induction. The design of this French study (Intergroupe Francophone de Cancerologie Thoracique-Groupe Francais de Pneumo-Cancerologie [IFCT-GFPC] 0502) randomly assigned patients to observation or two different maintenance regimens, gemcitabine, or erlotinib. Moreover, it mandated second-line therapy for all patients with pemetrexed. Since the study was designed before the interaction of pemetrexed with histology was known, 19% of patients in the observation group had squamous cell histology. Independently assessed PFS was longer in the gemcitabine arm (3.8 v 1.9 months; HR, 0.55; P Ͻ .001). OS was a secondary end point and with 69.6% of events having occurred, the HR of the comparison between gemcitabine and observation is 0.86 (95% CI, 0.66 to 1.12). Impressively, 81.9% of patients in the observation arm received US Food and Drug Administration-approved second-line therapy, which is the highest salvage therapy rate reported in maintenance trials and balances much better the two arms in terms of overall therapy delivered. Unfortunately, with about 150 patients randomly assigned in each arm, this trial may not have the power to detect any clinically meaningful survival differences.
Despite complete lack of randomized data, maintenance therapy with bevacizumab or cetuximab is currently recommended after induction with antibody containing chemotherapy, based on the design of ECOG 4599 and FLEX. 2
Switch-Maintenance Therapy
Switch-maintenance therapy involves the administration of an agent with established activity in advanced NSCLC, immediately after completion of the initial course of chemotherapy. Although any active agent against NSCLC could be considered for maintenance therapy, switch-maintenance trials thus far have only evaluated approved second-line agents (docetaxel, 16 ,17 erlotinib, 18 and pemetrexed 19 ).
Preclinical and clinical data have shown that taxanes, such as docetaxel, are active in platinum-resistant NSCLC, 20,21 indicating that the delivery of taxanes after platinum-based induction therapy using a switch-maintenance strategy may be a viable option. A phase III study involving 566 patients with stage IIIB/IV NSCLC evaluated this approach directly (Tables 3 and 4 ). 15, [22] [23] [24] [25] [26] The study evaluated the relative efficacy of docetaxel given either immediately after first-line therapy or at disease progression. This is the only study to date that has examined directly the issue of chemotherapy timing, since both groups were scheduled to receive the same regimen. Of the original cohort, 309 patients completed first-line treatment consisting of 4 cycles of carboplatin and gemcitabine and were randomly assigned to immediate or delayed docetaxel for a maximum of 6 cycles. Median PFS was significantly longer in the immediate versus the delayed docetaxel group (5.7 v 2.7 months; P ϭ .0001). There was also a nonsignificant trend toward longer OS in the immediate docetaxel group (12.3 v 9.7 months; P ϭ .0853). A significant proportion of patients in the delayed treatment arm never received docetaxel (although 63% were able to receive therapy), compared to the immediate arm, where almost all patients did. The major reason for not receiving chemotherapy in the delayed arm was significant symptomatic deterioration by the time disease progression occurred. Analysis of patients who actually received docetaxel revealed that OS was identical in both arms of the study (12.5 months), possibly indicating that the trend toward improved OS was because more patients in the immediate group were able to receive docetaxel treatment. Toxicity profiles were generally similar between the arms. Comparisons of QoL, measured during chemotherapy for patients in the immediate arm and during observation in the delayed arm, showed no significant differences.
The potential utility of early second-line therapy with the antifolate pemetrexed was investigated in a phase III trial. 23 A total of 663 patients who had not progressed after 4 cycles of platinum-based induction therapy were randomly assigned in a 2:1 ratio to receive pemetrexed plus BSC or placebo plus BSC. Pemetrexed was not used in the induction regimens. Patient characteristics were well-balanced between the two groups. Maintenance therapy significantly improved the independently assessed PFS Abbreviation: NR, not recorded.
‫ء‬
Peripheral squamous cell cancers. Based on its efficacy in advanced NSCLC, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib has also been evaluated as switch-maintenance therapy in three randomized phase III studies (Sequential Tarceva in Unresectable Lung Cancer [SATURN], ATLAS, and IFCT-GFCP 0502). Results from the SATURN study were recently published. 24 This trial evaluated erlotinib maintenance therapy at 150 mg/d versus placebo in 889 patients without disease progression after treatment with at least 4 cycles of standard first-line platinum-based doublet chemotherapy. Rash (erlotinib 60% v placebo 8%) and diarrhea (20% v 3%) were the most common toxicities, with most reported to be of grade 1/2. Patients in the erlotinib arm had significantly prolonged PFS compared with placebo, in both the unstratified (12.3 v 11.1 week; HR, 0.71; P Ͻ .001) and EGFR immunohistochemistry (IHC) -positive study populations (12.3 v 11.1 week; HR, 0.69; P Ͻ .001). More importantly, survival was increased in the erlotinib arm, both in the intent to treat population (12.0 v 11.0 months; HR, 0.81; P ϭ .0088) and in the subgroup of patients with wild-type EGFR (11.3 v 10.2 months; HR, 0.77; P ϭ .0243). Although 72% of patients in the placebo arm received second-line therapy, only 21% actually received an EGFR-TKI. Interestingly, subgroup analysis according to EGFR mutation status showed that the majority of the benefit was driven by the patients with wild-type, rather than mutant, EGFR tumors (HR, 0.77 v 0.83). 27 Biomarker analysis of the SATURN trial evaluated the role of EGFR copy number by fluorescent in situ hybridization (FISH; positive in 48%), EGFR expression by IHC (positive in 84%), K-ras mutation (positive in 18%), and EGFR mutation (positive in 11% of samples tested). 28 In this analysis, there was a significant interaction between the presence of EGFR mutation and treatment benefit with erlotinib, in terms of PFS (P Ͻ .001).
The ATLAS study compared bevacizumab plus erlotinib with bevacizumab plus placebo in 743 patients with advanced NSCLC without progression after 4 cycles of platinum doublet chemotherapy plus bevacizumab. 25 ATLAS is therefore unique among these trials, since its design incorporates standard bevacizumab maintenance in both arms. PFS was significantly longer in the combination maintenance group (4.76 v 3.75 months; HR, 0.722; P ϭ .0012). The 3-and 6-month PFS rates was 67.7% and 40.3% in the erlotinib arm, compared to 53.4% and 28.4% for the placebo arm. Not surprisingly, subgroup analysis showed a significant effect on PFS for never smokers treated with maintenance erlotinib (HR, 0.34). Biomarker status was available in 367 of the patients in the trial, and similar to SATURN, evaluated the influence of EGFR IHC (positive in 52% of available specimens), EGFR FISH (positive in 23.7%), EGFR mutation (positive in 14%), and K-ras mutation (positive in 25%) on PFS. 29 Patients who were EGFR FISH positive, EGFR mutated, and K-ras wild-type enjoyed the greatest benefit from therapy with erlotinib and bevacizumab in the maintenance setting (HR, 0.66, 0.44, and 0.67, respectively). OS, which was a secondary end point, showed a nonsignificant 2-month difference in favor of the experimental group (15.9 v 13.9 months; HR, 0.9; P ϭ .2686). The high baseline OS in the bevacizumab arm, the highest reported in maintenance trials, could be due to patient selection, or effect of bevacizumab in the maintenance setting. Potentially, the addition of another maintenance agent does not confer any additional benefit. Alternatively, based on the number of patients randomly assigned and the high survival attained by the bevacizumab only group, the study may not have had the power to detect OS differences. It has to be noted that the study closed after a second interim analysis confirmed the PFS superiority in the erlotinib arm, which limits the interpretation of this posthoc analysis.
The recently reported IFCT-GFPC 0502 compared erlotinib to observation after 4 cycles of cisplatin/gemcitabine. 15 As mentioned previously, patients were mandated to receive pemetrexed on progression, and indeed a large portion of these patients was treated (pemetrexed, 76.1%; erlotinib, 3.9%; and docetaxel, 1.9%). Baseline characteristics were balanced. Similar to the previous studies, PFS favored the erlotinib group (2.9 v 1.9 months; HR, 0.82; P ϭ .002). OS comparison showed an HR of 0.91 (95% CI, 0.80 to 1.04) in a preliminary evaluation. Although tissue was submitted for EGFR mutation analysis, results based on mutation status are not currently available. It is interesting, however, that there was no difference in the PFS HR between smokers and nonsmokers in this study (HR 0.79 for smokers and HR 0.88 for nonsmokers).
DISCUSSION
Optimizing the treatment of advanced NSCLC involves consideration of delivering the most effective therapies, in the right combination, at the right time, while minimizing toxic adverse effects and adverse effects on QoL. Approximately 40% to 60% of patients with advanced NSCLC complete 4 cycles of platinum-based chemotherapy without progression or unacceptable toxicity. For these patients, continuation of chemotherapy is a feasible option. The question of how to deliver this additional therapy is the subject of ongoing clinical research.
The US Food and Drug Administration and the European Commission approved pemetrexed in July 2009 as maintenance therapy for patients with nonsquamous histology, for whom disease has not progressed after platinum-based chemotherapy. 30, 31 Of interest, the European Medicines Agency (EMEA) specifically noted that first-line treatment should be a platinum doublet with gemcitabine, paclitaxel, or docetaxel. 30 Erlotinib as immediate treatment after first-line chemotherapy was also recently approved by the US Food and Drug Administration 32 and the EMEA. 33 It has to be noted that although the docetaxel study 22 was negative, the HR for PFS and OS was fairly consistent with the other switch-maintenance trials ( Table 5 ), suggesting that the lack of statistical significance may relate more to the power of the study than a lack of effectiveness of the strategy.
It is unclear whether the benefit seen in recent maintenance studies is the result of the early institution of noncrossresistant therapy or more practical considerations. Despite strong theoretical rationale, 34 the planned sequential delivery of noncrossresistant agents has not proven beneficial in advanced NSCLC. 35, 36 A maintenance approach may therefore represent the most effective way to deliver second-line therapy. This is an important point to consider since typically only approximately 60% of patients are able to receive second-line treatment. The IFCT-GFPC-0502 study is very critical in that respect, with more than 80% of patients in the control group actually receiving US Food and Drug Administrationapproved treatment. Unfortunately, the trial has limited power to detect survival differences.
A number of additional issues relevant to the delivery of chemotherapy in NSCLC are worth discussing. Who will receive second-line therapy? Results from the docetaxel study show that patients who actually receive chemotherapy in either arm have identical survival at 12.5 months. Although this is a biased analysis, it may suggest that timing is less important than the ability to receive therapy at time of progression. However, is it possible to predict who will receive secondline therapy? Currently, data are only available for the docetaxel study, where factors such as complete response/stable disease (SD), sex, PS, stage IIIB versus IV were examined; however, no characteristic was found that would predict for eventual second-line therapy in the control group.
How should we select patients, who will benefit from maintenance therapy? Results from the docetaxel study suggested that response patients might benefit more than patients with SD. The HR for PFS was 0.47 and 0.81, while for OS the HR was 0.61 and 1.02 for response and SD patients, respectively. Similarly, the PFS HR in the French study with continuation gemcitabine maintenance favored the responsive patients (HR, 0.44 v 0.68), while there was no difference in the switch-maintenance approach with erlotinib between response and SD patients (HR, 0.80 v 0.85, respectively). Subgroup analysis of the pemetrexed study showed improvement only for patients with SD at time of random assignment. 37 The HR for PFS was 0.53 for responders and 0.48 for SD patients, whereas the HR for OS was 0.90 and 0.68, respectively. Data from SATURN were concordant with the pemetrexed trial; patients with responsive tumors had an OS HR of 0.94 versus 0.72 for SD. 24 It is important to note that EMEA approved erlotinib only for patients with SD after 4 cycles of standard platinumbased first-line chemotherapy, although as it can be seen from the above the data is not consistent at all.
Another interesting point comes from the SATURN study, where the benefit in PFS was primarily seen in patients with EGFR mutations, whereas the benefit in OS was driven by EGFR wild-type patients. This suggests that in patients with EGFR mutant tumors, for whom highly effective salvage therapy exists, timing is less important. Unfortunately, such a beneficial effect is not seen with usual chemotherapy.
Results from the pemetrexed study clearly showed benefit only for patients with nonsquamous histology, presumably due to the higher level of thymidylate-synthase in squamous cell cancers. 38 Although the HR in the SATURN study also favored patients with adenocarcinoma histology, both in terms of PFS (HR 0.60 v 0.76 for squamous cell cancers) and OS (HR 0.77 v 0.86), benefit from erlotinib was seen in both groups. Similarly, there was no treatment-byhistology interaction in the immediate versus delayed docetaxel study or the IFCT-GFPC-0502 trial for either gemcitabine or erlotinib.
Biomarker analysis has suggested possible patient subgroups, which might derive greater or lesser benefit from treatment with EGFR-TKIs. It is clear that PFS, but not OS, is significantly better in patients with EGFR mutations. In the context of EGFR-mutant lung cancer,studiesoffirst-lineEGFR-TKIsversusstandardplatinumchemotherapy have demonstrated a large benefit in terms of response rate, PFS, and QoL favoring the TKIs. 39, 40 Even in the absence of a survival improvement, we feel that these patients are best served with first-line treatment with an EGFR-TKI, which should not be reserved for second-line or maintenance therapy. Patients with K-ras mutation, however, seem to have less benefit. In the SATURN trial, PFS was statistically significant only for patients with wild-type tumors (HR, 0.70; P ϭ .0009 v HR, 0.77; P ϭ .2246 for mutant tumors), although on further analysis there was no interaction with treatment effect for this variable (P ϭ .95). 41 Similarly, K-ras wild-type status was associated with a PFS HR of 0.67 (95% CI, 049 to 0.91) in the ATLAS study, compared to a HR of 0.93 (95% CI, 0.55 to 1.56) for mutant tumors. In addition, there is a long line of publications, which show questionable benefit to therapy with EGFR-TKIs for patients with K-ras mutant NSCLC, 42-44 and in one study, treatment with erlotinib was associated with significantly worse survival in such patients. 45 Although these data cannot be considered conclusive, a practice favoring treatment with EGFR-TKIs for K-ras wild-type patients is currently the most advisable approach.
Although the IFCT-GFPC 0502 is the only study to include both the switch and continuation-maintenance approaches within the same trial, the two experimental arms were compared separately to the control group, and not to each other. However, the HR for both PFS and preliminary OS analysis appeared to be more robust with continuation chemotherapy compared to switch erlotinib. The question is whether this difference, if real, reflects benefit from the strategy versus the agent used. At this point, all studies with proven OS benefit have followed a switch-maintenance strategy. On the basis of the design of the Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (JMEN) trial, it is unclear whether the beneficial effect of pemetrexed maintenance extends to patients treated initially with pemetrexed. Several phase III trials are underway to examine this issue. In the Point-Break study, patients are being randomly assigned to either the ECOG 4599 regimen (carboplatin, paclitaxel, and bevacizumab, followed by bevacizumab) or the Patel regimen (carboplatin, pemetrexed, and bevacizumab followed by pemetrexed and bevacizumab). In another important study, patients with SD or responsive disease after 4 cycles Apart from the ATLAS trial, results of recent maintenance studies do not take into account the use of bevacizumab. Results from a phase III trial (Gynecologic Oncology Group 218) in advanced ovarian cancer examining the use of maintenance bevacizumab were presented in the 2010 ASCO meeting. 46 Relative to patients treated with chemotherapy alone, the HR for progression or death was 0.908 (P ϭ .16) for the group treated with first-line chemotherapy/bevacizumab, but without maintenance. In contrast, the HR was 0.717 (P Ͻ .0001) for those patients treated with maintenance bevacizumab. These intriguing results suggest a beneficial antitumor effect of antiangiogenic maintenance therapy, which may translate in other tumor types as well. The Eastern Cooperative Oncology Group is planning a randomized trial of three different maintenance strategies in patients with NSCLC after four cycles of carboplatin, paclitaxel, and bevacizumab: pemetrexed alone, bevacizumab alone, or pemetrexed plus bevacizumab.
What is the most appropriate study end point? Debate on maintenance therapy is, in part, a debate about timing of therapy in NSCLC. Therefore, OS, and not PFS, is the most appropriate end point. Even if a survival benefit is demonstrated, patients often have different priorities, placing greater importance on improvements in QoL. 47 Older studies occasionally showed worsening in QoL with prolongation of chemotherapy, although such studies often included cisplatin regimens. More recent studies have shown no detriment in QoL when comparing different durations of chemotherapy 11 or when comparing delayed versus immediate second-line therapy. 22, 27 In the docetaxel study, there was no significant difference between the immediate docetaxel and delayed docetaxel arms with respect to global QoL (improvement: 15.6% for both arms; worsening: immediate 11.0% and delayed 18.4%; overall P ϭ .76). Symptom control data from the SATURN study augment this point: although there was no difference in time to deterioration in QoL by Functional Assessment of Cancer Therapy-Lung in the two arms (HR, 0.96), there was an improvement in time to pain and time to analgesic use in favor of the erlotinib arm (HR, 0.61 and 0.66, respectively). In the pemetrexed study, drug-related toxicity was greater for the pemetrexed arm, including anemia, fatigue, anorexia, and nausea. However, time to symptom worsening analysis favored pemetrexed maintenance for control of pain (6.1 v 4.6 months; P ϭ .041) and hemoptysis. 23 Ultimately, physicians and patients will have to decide on the timing of additional chemotherapy, based on prior treatment tolerance, the expected acute toxicities of the proposed regimen, and potential benefits in terms of survival and symptom control.
With regard to future developments in the treatment of patients with advanced NSCLC, special attention will be paid to the identification of patient subgroups more or less likely to benefit from maintenance therapy, as this approach becomes a new therapeutic option.
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